Novel Score Predicts Weight Loss With Semaglutide in T2D

TOPLINE: Patients with both type 2 diabetes (T2D) and obesity, who have a lower diabetes severity, as characterized by the individualized metabolic surgery (IMS) scoring system, achieve better weight loss outcomes with semaglutide. METHODOLOGY: Prior studies indicate that semaglutide leads to inferior weight loss outcomes in patients with obesity who have T2D vs those without …
Read More